TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02546661
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736
Study: NCT02546661
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 (durvalumab) + AZD1775
Study: NCT02546661
Drug: AZD9150
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 (durvalumab) + AZD9150
Study: NCT02537691
Drug: Oral Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids will be administered as per investigator discretion.
Study: NCT02028676
Drug: Arm A: ABC+3TC+NNRTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
Study: NCT02028676
Drug: Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
Study: NCT02028676
Drug: Once-daily ABC+3TC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02028676
Drug: Twice-daily ABC+3TC
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01871766
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage and route of administration:~During VAC chemotherapy:~* \< 3 years of age = 40 mg/kg IV~* ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~* oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)
Study: NCT01871766
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage and route of Administration:~Age ≥1 year, 37.5 mg/m\^2 IV over 1 hour x 2 days Age \<1 year, 18.75 mg/m\^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days.
Study: NCT01871766
Drug: ^1^1C-methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
Study: NCT02996773
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After transplant, given intravenously on day +3 as part of Phase 1b.
Study: NCT02033031
Drug: Lucentis intravitreal injection
Normalized name: Lucentis Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucentis intravitreal injection
Study: NCT00683657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, once daily, 4 weeks
Study: NCT00194779
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00194779
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00194779
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00194779
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03074630
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 9 weeks 10mg dapagliflozin once daily
Study: NCT03881696
Drug: Multi-Allergen Oral Immunotherapy
Normalized name: Finafta Multi Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-allergen OIT will be any of the following drug products: peanut, milk, egg, wheat, cashew, hazelnut, and walnut (all food protein flours).~A prescription for each participant for the appropriate dose of each of the allergens will be prepared. The pharmacist will compound the appropriate allergens and dispense the Multi-allergen OIT dose in a blinded (masked) fashion. The Clinical Research Unit (CRU) staff will administer food flour to the participant orally in an age-appropriate food vehicle (e.g., applesauce, pudding, etc.). Dosage will be administered according to the study protocol.
Study: NCT00852202
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules, oral administration, once daily dosing
Study: NCT00508430
Drug: ASP8825
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00508430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04821778
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1/PD-L1 Antibody
Study: NCT02773602
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
Study: NCT02051621
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
Study: NCT04541134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)
Study: NCT00715429
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
Study: NCT00504270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po daily
Study: NCT00504270
Drug: RG3421 120mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg po daily
Study: NCT00504270
Drug: RG3421 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg po daily
Study: NCT00261326
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg once daily
Study: NCT00261326
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium tablets once daily
Study: NCT02083627
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT03580473
Drug: SATURNO II association
Approvals — FDA: no, EMA: no, PMDA: no
Description: opthalmic solution, 4 times a day
Study: NCT03580473
Drug: Vigadexa®
Approvals — FDA: no, EMA: no, PMDA: no
Description: opthalmic solution, 4 times a day
Study: NCT03529201
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: painkiller during GA
Study: NCT01042769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo control po daily
Study: NCT00828165
Drug: ARRY-300, MEK inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, escalating
Study: NCT01527188
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sublingual tablet daily during 6 months
Study: NCT01839110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth twice per day for a total of 26 weeks.
Study: NCT03341390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of Placebo administered twice daily
Study: NCT02000453
Drug: GSK2586184 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
Study: NCT03843229
Drug: Cinobufacini injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
Study: NCT03843229
Drug: cinobufacini tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
Study: NCT01183676
Drug: DEPAKOTE® Tablets, 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 500 mg Tablet, under fed conditions
Study: NCT04313881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match magrolimab administered intravenously
Study: NCT00496665
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
Study: NCT00496665
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
Study: NCT02243553
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02859792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules 25 or 50 mg
Study: NCT00672074
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT02147548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02457039
Drug: Cytoxan-containing chemotherapy regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject shall receive oral administration or venous injection or both with adjuvant or neoadujuvant chemotherapy regimens, as decided by clinical oncologist.~In clinical practice, the most commonly used Cytoxan-containing regimens include but are not limit to:~AC (x4) \[Adriamycin + Cytoxan\], TC (x4) \[Taxotere + Cytoxan\], AC-P (4+4) \[Adriamycin + Cytoxan + Paclitaxel\], TAC (x6) \[Taxotere + Adriamycin + Cytoxan\], or AC-PH (4+4) \[Adriamycin + Cytoxan + Paclitaxel + Herceptin\].
Study: NCT01039701
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, oral, 3 times daily
Study: NCT04663139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01039701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, oral, 3 times daily, 4 weeks
Study: NCT01859481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
Study: NCT00536003
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
Study: NCT01022346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
Study: NCT01022346
Drug: RO5217790
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5217790 will be administered at a dose of 5\*10\^7 pfu subcutaneously on Days 1, 8, and 15.
Study: NCT01562938
Drug: MEDI-557
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-557 low-dose
Study: NCT03595644
Drug: TKI
Normalized name: Catkin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received EGFR-TKI treatment
Study: NCT02937168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
Study: NCT02639130
Drug: Exendin [9-39]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent
Study: NCT02639130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion as challenge agent
Study: NCT01562938
Drug: MEDI-557
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-557 high-dose
Study: NCT04659642
Drug: Fentanyl Citrate Injection
Normalized name: Fentanyl Citrate Injection
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the drug is given 15 minutes before the estimated end of surgery
Study: NCT02677116
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin administered IV.
Study: NCT00729833
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-751,871 IV, every 3 weeks
Study: NCT00979836
Drug: Calcium Dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/ three times/day for 6 months (capsules)
Study: NCT00347386
Drug: Drug: Zinc (zinc sulphate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissolvable tablet 10 mg. Once daily during the illness
Study: NCT00347386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, once daily
Study: NCT02457221
Drug: Cyclophosphamide injections
Normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous injection
Study: NCT01737580
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02029495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via subcutaneous injection until week 24.
Study: NCT02210104
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2 administered intravenously 2 days prior to T cell infusion.
Study: NCT02126826
Drug: Placebo to BI 1026706
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Rising Doses (oral solution / tablet, identical to active treatment)
Study: NCT03410056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as a subcutaneous injection.
Study: NCT00808314
Drug: Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
Study: NCT00853099
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03742193
Drug: GD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle: gemcitabine 900 mg/m\^2 over 90 min on Day 1, and gemcitabine 900 mg/m\^2 and docetaxel 75 mg/m\^2 on Day 8. Every 21 days were eligible.~1\~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken.
Study: NCT01078870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1\~2#/cap QD
Study: NCT00239174
Drug: SR147778
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00827918
Drug: MK-8998
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
Study: NCT04588389
Drug: Multimodal Pharmacological Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care multimodal pharmacological management
Study: NCT00827918
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching olanzapine tablets and MK-8998 capsules
Study: NCT01968564
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar and other inert substances
Study: NCT00131599
Drug: 5FU/LV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU/LV
Study: NCT03240783
Drug: Normal Saline Flush, 0.9% Injectable Solution
Normalized name: Normal Saline Flush, 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedural agents. The local anaesthetic preparation used with the Normal Saline Flush, 0.9% Injectable Solution, will be standardized to replicate current radiology interventional practices: either local anaesthetic bupivacaine 0.5% (1ml) or local anaesthetic lignocaine 1% (1ml).
Study: NCT01196650
Drug: IN 10 003 formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01196650
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03001453
Drug: 0.25% Bupivacaine with epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% bupivacaine with epinephrine
Study: NCT04148573
Drug: NFX88 - 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a day
Study: NCT04148573
Drug: NFX88 - 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a day
Study: NCT04148573
Drug: NFX88 - 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a day
Study: NCT04148573
Drug: PLACEBO - 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a day
Study: NCT03443492
Drug: Leucovorin(oral )
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intervention is administered to patients in this Arm.
Study: NCT03443492
Drug: Leucovorin(IV)
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intervention is administered to patients in this Arm.
Study: NCT01967524
Drug: Ropivacaïne
Approvals — FDA: no, EMA: no, PMDA: no
Description: D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain Questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36).
Study: NCT04238650
Drug: EU approved Avastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
Study: NCT00789191
Drug: sulphonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
Study: NCT00002803
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002803
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00990691
Drug: Administration of a high dose of desipramine
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 50 mg ;~* From 26 to 35 kg : 75 mg ;~* From 36 to 45 kg : 100 mg ;~* \> 46 kg : 150 mg.
Study: NCT00990691
Drug: Administration of a low dose of desipramine
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 25 mg ;~* From 26 to 35 kg : 50 mg ;~* From 36 to 45 kg : 75 mg ;~* \> 46 kg : 100 mg.
Study: NCT00990691
Drug: Administration of a placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a daily dose of placebo
Study: NCT03036163
Drug: PBTZ169 - 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of PBTZ169 (1 capsule) orally once in fasting state
Study: NCT03036163
Drug: PBTZ169 - 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
Study: NCT03036163
Drug: PBTZ169 - 160 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
Study: NCT03036163
Drug: PBTZ169 - 320 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
Study: NCT03036163
Drug: PBTZ169 - 640 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
Study: NCT01436955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses
Study: NCT01436955
Drug: RG1662
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts receiving multiple oral doses
Study: NCT04620408
Drug: SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
Study: NCT00629018
Drug: Bone Marrow Stimulation
Normalized name: Sus scrofa bone marrow preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
Study: NCT01283412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) iv. during the operation and stoped 30min before end of the surgery
Study: NCT04337814
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral analgesic syrup (non-steroidal anti inflammatory drug)
Study: NCT04337814
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup similar to Ibuprofen
Study: NCT04337814
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream similar to EMLA